Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.
Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.|Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
Raffaella
R
Ravinetto
Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.
Anja
A
De Weggheleire
Department Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.|Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
Thomas P C
TP
Dorlo
University of Antwerp, Antwerp, Belgium.
Sven
S
Francque
Sihanouk Hospital Centre of Hope, Phnom Penh, Cambodia.
An
A
Sokkab
QUAMED, Institute of Tropical Medicine, Antwerp, Belgium.
Corinne
C
Pouget
Public Health Department, Institute of Tropical Medicine, Antwerp, Belgium.
Bruno
B
Meessen
INSERM U 1058, Montpellier, France.
Patricia
P
Tabernero
Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Mahosot Hospital, Vientiane, Lao PDR.|Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK.|Worldwide Antimalarial Resistance Network, Churchill Hospital, Oxford University, Oxford, UK.|London School of Hygiene and Tropical Medicine, London, UK.
Paul N
PN
Newton
Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.
Lut
L
Lynen
D015081:2-Naphthylamine; D000813:Anilides / Q000627:therapeutic use; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D002219:Carbamates / Q000627:therapeutic use; D003521:Cyclopropanes; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D004359:Drug Therapy, Combination / Q000191:economics; D005252:Fees, Pharmaceutical; D005449:Fluorenes / Q000627:therapeutic use; D006297:Health Services Accessibility / Q000191:economics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives; D011634:Public Health / Q000639:trends; D011759:Pyrrolidines; D011785:Quality Assurance, Health Care / Q000191:economics* / Q000331:legislation & jurisprudence; D011786:Quality Control; D019438:Ritonavir / Q000627:therapeutic use; D000069616:Simeprevir / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D014542:Uridine Monophosphate / Q000031:analogs & derivatives / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives
D000813:Anilides; D000998:Antiviral Agents; D001562:Benzimidazoles; D002219:Carbamates; D003521:Cyclopropanes; D005449:Fluorenes; D007093:Imidazoles; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D011759:Pyrrolidines; D013449:Sulfonamides; C000595958:ledipasvir, sofosbuvir drug combination; C586094:ombitasvir; D014498:Uracil; D011392:Proline; D000069616:Simeprevir; D015081:2-Naphthylamine; C588260:dasabuvir; D014542:Uridine Monophosphate; D014633:Valine; C549273:daclatasvir; D019438:Ritonavir; C585405:paritaprevir; D000069474:Sofosbuvir
access to medicines; counterfeit medicines; essential medicines; hepatitis C; quality of medicines; substandard medicines
PLoS Negl Trop Dis. 2012;6(5):e1544
22666507
Liver Int. 2016 Jul;36(7):925-8
27306302
Lancet Neurol. 2015 Nov;14(11):1075-6
26466777
Lancet. 2015 Nov 14;386(10007):1917
26841732
Trop Med Int Health. 2008 Aug;13(8):1062-72
18631318
J Public Health Policy. 2014 May;35(2):137-61
24430804
Hepat Med. 2015 Nov 02;7:51-70
26586968
Health Policy. 2014 Sep;117(3):328-33
25110297
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
25086286
Trends Pharmacol Sci. 2010 Mar;31(3):99-101
20117849
Lancet Glob Health. 2015 Nov;3(11):e676-7
26475012
J Virus Erad. 2016 Jan 01;2(1):28-31
27482432
Clin Infect Dis. 2016 Mar 1;62(5):561-7
26611779
Malar J. 2009 Nov 11;8:253
19906307
Bull World Health Organ. 2015 Nov 1;93(11):799-805
26549908
Lancet. 2012 Mar 24;379(9821):1084-5
22394558
Malar J. 2014 Apr 08;13:139
24712972
J Public Health Policy. 2015 Nov;36(4):384-9
26178809
Lancet Infect Dis. 2016 Sep;16(9):e196-e201
27421993
BMJ. 2016 Aug 23;354:i4524
27552835
Bull World Health Organ. 2010 Jun;88(6):402
20539847
N Engl J Med. 2009 Jul 30;361(5):455-67
19641202
Lancet. 2015 Oct 24;386(10004):1601-3
26595616
N Engl J Med. 2015 Dec 31;373(27):2678-80
26575359
Lancet Glob Health. 2015 Feb;3(2):e73-4
25617196
Therap Adv Gastroenterol. 2015 Sep;8(5):298-312
26327920
Clin Infect Dis. 2014 Apr;58(7):928-36
24399087
BMJ. 2015 Oct 20;351:h5554
26491096